Academic Journal
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
| العنوان: | Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors |
|---|---|
| المؤلفون: | Fucà, Giovanni, Corti, Francesca, Ambrosini, Margherita, Intini, Rossana, Salati, Massimiliano, Fenocchio, Elisabetta, Manca, Paolo, Manai, Chiara, Daniel, Francesca, Raimondi, Alessandra, Morano, Federica, Corallo, Salvatore, Prisciandaro, Michele, Spallanzani, Andrea, Quarà, Virginia, Belli, Carmen, Vaiani, Marta, Curigliano, Giuseppe, Cremolini, Chiara, De Braud, Filippo, Di Bartolomeo, Maria, Zagonel, Vittorina, Lonardi, Sara, Pietrantonio, Filippo |
| المساهمون: | G. Fucà, F. Corti, M. Ambrosini, R. Intini, M. Salati, E. Fenocchio, P. Manca, C. Manai, F. Daniel, A. Raimondi, F. Morano, S. Corallo, M. Prisciandaro, A. Spallanzani, V. Quarà, C. Belli, M. Vaiani, G. Curigliano, C. Cremolini, F. De Braud, M. Di Bartolomeo, V. Zagonel, S. Lonardi, F. Pietrantonio |
| بيانات النشر: | BioMed Central (BMC) |
| سنة النشر: | 2021 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | gastrointestinal neoplasm, immunotherapy, tumor biomarkers, Settore MED/06 - Oncologia Medica |
| الوصف: | Background Immune checkpoint inhibitors (ICIs) are the new standard of care in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Since tumor response dynamic parameters already shown a strong association with survival outcomes in patients with mCRC treated with first-line therapy, we investigated the association of early tumor shrinkage (ETS) and depth of response (DoR) in patients with MSI-H/dMMR mCRC treated with ICIs. Methods This is a retrospective, multicenter, cohort study in patients with dMMR and/or MSI-high mCRC treated with ICIs (anti-PD-1/PD-L1 with or without anti-CTLA-4 agents) with measurable disease and at least one post-baseline radiological disease reassessment. The Kaplan-Meier method and Cox proportional-hazards regression models were used for survival analyses. A maximally selected statistics method in a Cox regression model for progression-free survival (PFS) was used to determine the optimal cut-offs for ETS and DoR. Results We included a total of 169 patients: 116 (68.6%) were treated with anti-PD-1 monotherapy, whereas 53 (31.4%) with anti-PD-1 plus anti-CTLA-4 agents. Patients with primary progressive disease (N=37, 21.9%), experienced an extremely poor overall survival (OS) and were evaluated separately. In patients with clinical benefit, we observed a significant association between ETS and DoR with both OS and PFS, and we identified a relative reduction of at least 1% as the optimal cut-off for ETS and a relative reduction of at least 50% as the optimal cut-off for DoR. Conclusions ETS and DoR are important prognostic factors in patients with MSI-high mCRC treated with ICIs that might be useful to design treatment intensification/deintensification strategies. A prospective validation of both is warranted. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/33849927; info:eu-repo/semantics/altIdentifier/wos/WOS:000641483700003; volume:9; issue:4; numberofpages:9; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/2434/835832; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85104132199 |
| DOI: | 10.1136/jitc-2021-002501 |
| الاتاحة: | http://hdl.handle.net/2434/835832 https://doi.org/10.1136/jitc-2021-002501 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.42AFCEA4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/jitc-2021-002501 |
|---|